Gasogut-D Capsule SR contains a combination of Domperidone 30mg and Esomeprazole 40mg, formulated to manage gastrointestinal disorders characterized by acid reflux, heartburn, and delayed gastric emptying. Domperidone is a peripheral dopamine D2 receptor antagonist that enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, resulting in decreased acid production and promoting healing of acid-related mucosal damage. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, improving efficacy and patient compliance. Gasogut-D Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, and other acid-peptic disorders where both acid suppression and enhanced gastric motility are desired. It should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or those taking medications that may interact with domperidone or esomeprazole. Common side effects may include headache, dry mouth, abdominal discomfort, and rare extrapyramidal symptoms. Regular monitoring is recommended during prolonged therapy.